RegeneRx Biopharmaceuticals, Inc.
RGRXOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$898
P/E Ratio—
52W High$0.163
52W Low$0.0002
RegeneRx Biopharmaceuticals, Inc. (RGRX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RGRX · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2023Report Date: Mar 31, 2023EPS Actual
-$0.00
Revenue
$0.00B
Fiscal Period
Q1 FY2023
FY ends December
Report Date
Mar 31, 2023
After Market Close
RGRX reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$-0.11
Rev. $0.17B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$-0.11
Rev. Est.$0.17B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| — Q1 FY2023 | Mar 31, 2023 | — | -$0.00 | — | $0.00B | — | — |
| — Q4 FY2022 | Dec 31, 2022 | — | -$0.00 | — | $0.00B | — | — |
| — Q3 FY2022 | Sep 30, 2022 | — | -$0.00 | — | $0.00B | — | — |
| — Q2 FY2022 | Jun 30, 2022 | — | -$0.00 | — | $0.00B | — | — |
| — Q1 FY2022 | Mar 31, 2022 | — | -$0.00 | — | $0.00B | — | — |
| — Q4 FY2021 | Dec 31, 2021 | — | -$0.00 | — | $0.00B | — | — |
| — Q4 FY2021 | Nov 15, 2021 | — | -$0.00 | — | $0.00B | — | — |
| — Q3 FY2021 | Aug 6, 2021 | — | -$0.00 | — | $0.00B | — | — |
Q1 FY2023
Mar 31, 2023
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2022
Dec 31, 2022
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2022
Sep 30, 2022
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2022
Jun 30, 2022
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2022
Mar 31, 2022
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2021
Dec 31, 2021
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2021
Nov 15, 2021
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q3 FY2021
Aug 6, 2021
EPS Actual
-$0.00
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2017 | $0.00 | $0.00 | $0.00 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2017 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q1 FY2023 | Mar 31, 2023 | — | $10.75 | $10.50 | -2.33% |
| — Q4 FY2022 | Dec 31, 2022 | — | $13.89 | $12.75 | -8.21% |
| — Q3 FY2022 | Sep 30, 2022 | — | $16.00 | $14.00 | -12.50% |
| — Q2 FY2022 | Jun 30, 2022 | — | $17.00 | $15.50 | -8.82% |
| — Q1 FY2022 | Mar 31, 2022 | — | $17.90 | $18.00 | +0.56% |
| — Q4 FY2021 | Dec 31, 2021 | — | $16.00 | $16.00 | +0.00% |
| — Q4 FY2021 | Nov 15, 2021 | — | $16.98 | $16.50 | -2.83% |
| — Q3 FY2021 | Aug 6, 2021 | — | $27.87 | $27.95 | +0.29% |
Q1 FY2023-2.33%
Report Date
Mar 31, 2023
EPS Beat/Miss
—
Price Before
$10.75
Price After
$10.50
Q4 FY2022-8.21%
Report Date
Dec 31, 2022
EPS Beat/Miss
—
Price Before
$13.89
Price After
$12.75
Q3 FY2022-12.50%
Report Date
Sep 30, 2022
EPS Beat/Miss
—
Price Before
$16.00
Price After
$14.00
Q2 FY2022-8.82%
Report Date
Jun 30, 2022
EPS Beat/Miss
—
Price Before
$17.00
Price After
$15.50
Q1 FY2022+0.56%
Report Date
Mar 31, 2022
EPS Beat/Miss
—
Price Before
$17.90
Price After
$18.00
Q4 FY2021+0.00%
Report Date
Dec 31, 2021
EPS Beat/Miss
—
Price Before
$16.00
Price After
$16.00
Q4 FY2021-2.83%
Report Date
Nov 15, 2021
EPS Beat/Miss
—
Price Before
$16.98
Price After
$16.50
Q3 FY2021+0.29%
Report Date
Aug 6, 2021
EPS Beat/Miss
—
Price Before
$27.87
Price After
$27.95
Beat Rate0 / 8 quarters
Largest Move-12.50% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RGRX ends December
RegeneRx Biopharmaceuticals, Inc. (RGRX) most recently reported earnings on March 31, 2023 for Q1 FY2023, posting EPS of $-0.00 (in line with the analyst consensus of —). The next RGRX earnings date is expected around September 1, 2026.
Each quarter, investors track RGRX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RGRX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RGRX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RGRX earnings · 4 questionsRegeneRx Biopharmaceuticals, Inc.'s next earnings report is expected around September 1, 2026. RGRX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RGRX historically reports after market close (AMC).
RGRX earnings datewhen is RGRX earningsRGRX next earnings datewhen does RGRX report earningsRGRX earnings calendar
▸ Source: FMP · RegeneRx Biopharmaceuticals, Inc. SEC filings · US GAAP · RegeneRx Biopharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026